EUCTR2020-004844-27-IT进行中（未招募）1 期
SURE-01_An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy - SURE-01
OSPEDALE SAN RAFFAELE0 个研究点目标入组 56 人开始时间: 2021年6月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •¿ Female or male subjects, >18 years of age, able to understand and give written informed consent
- •¿ Histopathologically confirmed urothelial carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) transitional cell pattern.
- •¿ Fit and planned for RC (according to local guidelines).
- •¿ ECOG performance status score of 0 or 1
- •¿ Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation (Hemoglobin = 9 g/dL, ANC = 1,500/ mm3, and Platelets
- •= 100,000/ µL)
- •¿ Adequate hepatic function (Bilirubin = 1.5 IULN, AST and ALT = 2.5 x IULN or = 5 x IULN if known liver metastases and serum albumin >3 g/dl)
- •¿ Creatinine clearance =30 mL/min as assessed by the Cockcroft-Gault equation
- •¿ Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication, and must not be lactating. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- •¿ Female subjects of childbearing potential must be willing to use 2 methods of birthcontrol or be surgically sterile or abstain from heterosexual activity for the course of the
- •study through 6 months after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from
- •menses for >2 years
- •¿ Male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 3 months after the last dose of study therapy.
- •¿ Clinical stage defining clinical T2-T4N0M0 disease by CT (or MRI) + PET/CT (within 4 weeks of randomization by RECIST v1.1).
- •¿ The patient accepts to undergo radical cystectomy.
- •¿ Ineligibility to receive cisplatin-based neoadjuvant chemotherapy based on Galsky’s criteria OR refusal to receive neoadjuvant cisplatin-based chemotherapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •1. Has received prior systemic anti-cancer therapy including investigational agents and immunotherapy.
- •2. Has received prior radiotherapy on the bladder tumor.
- •3. Refusal to undergo RC.
- •4. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
- •Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
- •5. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- •6. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. Participants with low-risk early stage prostate cancer defined as follows are not excluded; Stage T1c or T2a with a Gleason score = 6 and prostatic-specific antigen (PSA) < 10 ng/mL either treated with
- •definitive intent or untreated in active surveillance that has been stable for the past year prior to study allocation.Women who are pregnant or lactating
- •7. Has severe hypersensitivity (=Grade 3) to sacituzumab govitecan and/or any of its excipients.
- •8. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •9. Have active cardiac disease, defined as:
- •Myocardial infarction or unstable angina pectoris within 6 months of C1D1
- •History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation
- •NYHA Class III or greater congestive heart failure or left ventricular ejection fraction of < 40%
- •10. Have known history of HIV-1/2 with uncontrolled viral load.
- •11. Have active HBV or HCV. In subjects with a history of HBV or HCV, subjects with detectable viral loads will be excluded.
- •12. Have other concurrent medical or psychiatric conditions that, in the Investigator’s opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
研究者
相似试验
进行中（未招募）
1 期
SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapymuscle-invasive bladder cancerMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864EUCTR2020-004876-16-ITOSPEDALE SAN RAFFAELE48
进行中（未招募）
1 期
AMuscle-invasive urothelial bladder cancer before cystectomyMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2015-002055-10-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI90
进行中（未招募）
1 期
ET for the prevention of CMV infection/disease in pediatric HSCT recipientsCytomegalovirus (CMV) infection in pediatric allogeneic HSCT recipientsMedDRA version: 20.1Level: PTClassification code 10011831Term: Cytomegalovirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001326-25-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc65
进行中（未招募）
1 期
ET for the prevention of CMV infection/disease in pediatric HSCT recipientsEUCTR2018-001326-25-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc60
进行中（未招募）
1 期
ET for the prevention of CMV infection/disease in pediatric HSCT recipientsCytomegalovirus (CMV) infection in pediatric allogeneic HSCT recipientsMedDRA version: 20.1Level: PTClassification code 10011831Term: Cytomegalovirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001326-25-Outside-EU/EEAMerck Sharp & Dohme LLC